Physician profile
Mohammad E Thawabi
NPI 1356730881
$10,980.58
in general payments reported to CMS, 2019-2025
29 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,323 · 2020: $479 · 2021: $1,912 · 2022: $2,904 · 2023: $561 · 2024: $396 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,822.16 | 2019 | |
| Terumo Medical Corporation | $1,523.65 | 2019-2023 | R2p Misago |
| Abbott Laboratories | $1,072.20 | 2019-2025 | Amplatzer Talisman, Xience Skypoint, Perclose Proglide |
| Cardiovascular Systems INC. | $1,043.95 | 2019-2023 | Diamondback Peripheral |
| Novartis Pharmaceuticals Corporation | $959.22 | 2019-2024 | |
| Abiomed | $590.97 | 2019-2025 | |
| Amgen INC. | $499.46 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $489.01 | 2019-2022 | |
| Boston Scientific Corporation | $456.65 | 2019-2025 | Watchman Flx, Accolade Sr |
| Medtronic, INC. | $410.08 | 2021-2024 | Onyx Frontier, In.Pact Admiral, Spiderfx |
| Bard Peripheral Vascular, INC. | $367.52 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.84 | 2020-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $274.60 | 2019-2024 | Xarelto |
| Endotronix, INC. | $190.49 | 2021-2022 | |
| Pfizer INC. | $190.00 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $134.72 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $119.65 | 2019-2023 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $114.30 | 2019-2025 | Evkeeza |
| Esperion Therapeutics, INC. | $92.93 | 2021-2022 | |
| Livanova USA, INC. | $90.75 | 2023 | Tandemlife |
| Merck Sharp & Dohme LLC | $49.07 | 2023 | Verquvo |
| Cvrx, INC. | $33.42 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.31 | 2019-2022 | |
| Shockwave Medical, INC | $32.37 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Otsuka America Pharmaceutical, INC. | $20.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.45 | 2023 | |
| Cardiva Medical, INC. | $17.65 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Chiesi USA, INC. | $15.57 | 2025 | Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Thawabi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.